Treatment Patterns of Neratinib in HER2+ EBC in China
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 500
- Registration Number
- NCT05491057
- Locations
- 🇨🇳
Medical Affair, Shanghai, China
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 815
- Registration Number
- NCT05270044
- Locations
- 🇨🇦
Toronto Sunnybrook Hospital, Toronto, Ontario, Canada
🇦🇹Krankenhaus der Elisabethinen Linz, Linz, Austria
ðŸ‡ðŸ‡ºDebreceni Egyetem, Debrecen, Hungary
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 63
- Registration Number
- NCT05195632
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳Sichuan Cancer Hospital, Chengdu, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 14
- Registration Number
- NCT05103891
- Locations
- 🇫🇷
Biotrial, Rennes, France
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 103
- Registration Number
- NCT05004350
- Locations
- 🇨🇳
Fujian Medical University - Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 3
- Registration Number
- NCT05003622
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 400
- Registration Number
- NCT04913285
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
- Conditions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 400
- Registration Number
- NCT04911998
- Locations
- 🇵🇹
Hospital Evora, Evora, Portugal
Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 146
- Registration Number
- NCT04875026
- Locations
- 🇩🇪
Kath. Klinikum Bochum St. Josef-Hospital, Bochum, Germany
🇩🇪MVZ Dermatologisches Zentrum Bonn GmbH, Bonn, Germany
🇫🇷CHU St Etienne Hopital Nord, Saint-Étienne, France
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Pierre Fabre Medicament
- Registration Number
- NCT04759846
- Locations
- 🇨🇿
Fakultni nemocnice Olomouc, Olomouc, Czechia
🇨🇿Fakultni Nemocnice Kralovske Vinohrady, Praha, Czechia
🇪🇸all D'Hebron Insitute of Oncology, Barcelona, Spain